Skip to main content
Normal View

Dáil Éireann debate -
Tuesday, 22 Oct 2002

Vol. 555 No. 5

Written Answers. - Cancer Screening Programme.

Seán Power

Question:

309 Mr. S. Power asked the Minister for Health and Children if recent figures indicate an increase in the occurrence of breast cancer; his plans to increase the availability of BreastCheck throughout the country; and if he will make a statement on the matter. [19272/02]

The most recent report of the National Cancer Registry, Cancer in Ireland: 1994 to 1998, Incidence, Mortality, Treatment and Survival, indicate that there is evidence of a divergence between female incidence and mortality rates, with a significant upward trend in breast cancer incidence in women under 65 years and downward trends in mortality rates in all age groups combined. These findings may be the result of improvements in treatment and-or increased screening. There were no significant trends in incidence or mortality for women aged 65 and over. The clear margin between the incidence and mortality trends reflects the fact that survival chances from breast cancer are good. The National Cancer Registry report that this divergence in the trends is expected to continue as a result of continuing improvements in treatments and also as a result of BreastCheck, the national breast screening programme. The programme commenced in March 2000 with phase one of the programme covering the Eastern Regional Health Authority, Midland Health Board and North-Eastern Health Board areas. Screening is being offered free of charge to all women in those areas in the target age group 50 to 64 years of age. The target population consists of approximately 136,000 women and it represents about 50% of the national target population. I understand that BreastCheck is on target to complete phase one of the programme by December 2002. To end August 2002, 91,906 women had been called for screening and 68,184 women have been screened, representing an uptake of 74%.

The decision to proceed on a phased basis is a reflection of the complexities involved in the screening process and it is essential that the pro gramme is driven by international quality assurance criteria and best practice. The board of BreastCheck has recently submitted a business plan to my Department for the national expansion of the programme. My Department is currently discussing the plan with BreastCheck, especially the linkages with the existing symptomatic breast disease services. I am committed to the national extension of BreastCheck and a decision in relation to this will be considered in the context of the overall investment programme for cancer services for 2003. Any woman irrespective of her age or residence, who has immediate concerns or symptoms should contact her GP who, where appropriate, will refer her to the symptomatic services in her area.
Top
Share